Edgar Filing: Evoke Pharma Inc - Form 4

Evoke Pharma Form 4											
if no longer subject to Section 16. Form 4 or Form 5 obligations may contin	 RM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 							OMB APPROVAL OMB 3235-0287 Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5			
(Print or Type Re	sponses)										
CARLSON MARILYN R. Symbol			mbol	er Name and Ticker or Trading Pharma Inc [EVOK]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O EVOKE LOMAS SAN SUITE 270	Date of Earliest Tr fonth/Day/Year) 5/29/2014	ransaction			Director 10% Owner XOfficer (give title Other (specify below) below) Chief Medical Officer						
	(Street)	If Amendment, Daed(Month/Day/Year	-			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 					
	ACH, CA 9207						Form filed by M Person	More than One Re	porting		
(City)	(State) (Zip)	Table I - Non-I	Derivative	Securi	ties Acq	uired, Disposed o	f, or Beneficial	ly Owned		
	2. Transaction Date (Month/Day/Year)	Execution Dates any	ate, if Transacti Code /Year) (Instr. 8)	on(A) or D (D)	4 and (A) or	d of 5) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	08/29/2014		J <u>(1)</u>	1,256	A	\$ 5.67	1,256	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Evoke Pharma Inc - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3,		Date	7. Title Amoun Underl Securit (Instr.	nt of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
Peno	rting ()	wnore	Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
CARLSON MARILYN R. C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE, SUITE 270 SOLANA BEACH, CA 92075			Chief Medical Officer				
Signatures							
/s/ Matthew J. D'Onofrio, Attorney-in-fact for M Carlson	arilyn R.		09/03/2014				
<u>**</u> Signature of Reporting Person			Date				
Explanation of Responses:							

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.